A Phase 1 interventional study of HS-20118 and HS-20118 in Healthy Participants, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a single-center, open-label, randomized, four-period dosing clinical study designed to evaluate the pharmacokinetic characteristics of HS-20118 under different dosing conditions in healthy participants. It is planned to enroll 32 healthy participants.
This is a single-center, open-label, randomized, 4-period dosing clinical study. Eligible participants will be randomized into two groups: Group 1 and Group 2. A 42-day washout period will separate each consecutive period.
Dosing Conditions for Group 1:
Participants will be required to fast overnight for at least 10 hours prior to dosing across all 4 periods. In each period, a dose of 400 mg will be administered with approximately 180 mL of water. Water intake will be restricted from 2 hours pre-dose until 2 hours post-dose (except for the water used for dosing and beverages provided with the low-fat/high-fat meals). In Period 1, a low-fat meal will be consumed 1 hour post-dose; in Period 2, a low-fat meal will be consumed 30 minutes post-dose; in Period 3, a low-fat meal will be consumed 2 hours post-dose; and in Period 4, a high-fat meal will be consumed 30 minutes post-dose.
Dosing Conditions for Group 2:
In each period, a dose of 400 mg will be administered with approximately 180 mL of water, and water intake will be restricted from 2 hours pre-dose until 2 hours post-dose (except for the water used for dosing and beverages provided with the low-fat/high-fat meals).
Periods 1 to 3: Participants will fast for 6 hours prior to dosing in Periods 1 and 3, and for 4 hours prior to dosing in Period 2. Prior to the initiation of the pre-dose fast in each period, a low-fat meal must be completed within 15 minutes, following a fast of at least 4 hours before this meal. A low-fat meal will be consumed 2 hours post-dose in Periods 1 and 2, and 30 minutes post-dose in Period 3.
Period 4: Participants will fast for 6 hours prior to dosing. A high-fat meal must be completed within 30 minutes prior to the initiation of the pre-dose fast, following a fast of at least 4 hours before this meal. A high-fat meal will be consumed 30 minutes post-dose.
Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HS-20118
Drug: HS-20118
HS-20118 tablets will be administered orally as a single dose of 400 mg (two 200 mg tablets) with approximately 180 mL of water in each of the 4 treatment periods, separated by a washout period of at least 42 days. In each period, the drug will be administered under specific dietary and fasting conditions.
HS-20118 tablets will be administered orally as a single dose of 400 mg (two 200 mg tablets) with approximately 180 mL of water in each of the 4 treatment periods, separated by a washout period of at least 42 days. In each period, the drug will be administered under specific dietary and fasting conditions.
Cmax of HS-20118 under different administration conditions
Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
Tmax of HS-20118 under different administration conditions
Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
AUC0-t of HS-20118 under different administration conditions
Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
AUC0-inf of HS-20118 under different administration conditions
Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
t1/2 of HS-20118 under different administration conditions
Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
CL/F of HS-20118 under different administration conditions
Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
Vd/F of HS-20118 under different administration conditions
Time frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), and Safety Abnormalities
Incidence, seriousness, and severity of adverse events will be evaluated. Safety assessments will include vital signs, 12-lead electrocardiogram (ECG) parameters, physical examinations, and clinical laboratory tests.
Time frame: Day 1 up to Day 183
Incidence of Anti-drug antibody (ADA)
Blood samples will be analyzed for the presence of ADAs against HS-20118
Time frame: Pre-dose on Day 1 up to Day 162
Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HS-20118
Jiangsu Hansoh Pharmaceutical Co., Ltd. →